MedPlus Health Services Limited has disclosed to stock exchanges that its subsidiary company has received a regulatory action from Karnataka's drug control authorities. The company filed the disclosure on December 10, 2025, in compliance with SEBI listing regulations.

Regulatory Action Details

Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, received a suspension order for its drug license from the Assistant Director, Drugs Control Administration, Hubli Circle-Hubli, Karnataka. The order was received on December 9, 2025.

Legal Framework and Compliance

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed this information pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Financial Impact

The company has quantified the potential financial impact of this regulatory action:

Disclosure and Transparency

MedPlus Health Services has ensured proper disclosure of this regulatory development across multiple platforms. The information has been made available on the company's official website at www.medplusindia.com , as well as on the websites of both stock exchanges - BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Limited ( www.nseindia.com ). The disclosure was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer, demonstrating the company's commitment to regulatory compliance and transparency with stakeholders.

Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has encountered regulatory challenges in Karnataka. The company recently received suspension orders for drug licenses at two of its stores in the state, as disclosed in a regulatory filing.

Suspension Details

The Assistant Director of Drugs Control Administration, Hubli Circle-Hubli, Karnataka, issued suspension orders for two Optival Health Solutions stores:

Regulatory Context

The suspensions were imposed under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The orders highlight the stringent regulatory environment in which pharmaceutical retail operations must function.

Financial Impact

While the immediate financial impact appears limited, with a combined potential revenue loss of approximately Rs 3.49 lacs for the affected stores, the incident underscores the importance of regulatory compliance in the pharmaceutical retail sector.

Company Response

Medplus Health Services Limited promptly disclosed this information to the stock exchanges, in compliance with SEBI regulations. The company's transparency in reporting such incidents is crucial for maintaining investor trust and adhering to corporate governance standards.

This development serves as a reminder of the regulatory risks faced by companies in the pharmaceutical retail space and the potential operational and financial consequences of non-compliance.